Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP3 | P08254 | 1/20 | 0.58 |
| ▸ | TACR1 | P25103 | 9/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931193 | 1.00 | MAPT (0.66) | MAPTTP53LMNATHRBMEN1 | |
| SCHEMBL12966271 | 1.00 | MAPT (0.66) | MAPTTP53LMNATHRBMEN1 | |
| Hydrochloric Acid SCHEMBL12819455 | 0.99 | MAPT (0.65) | MAPTTP53LMNATHRBMEN1 | |
| SCHEMBL9969972 | 0.96 | KMT2A (0.68) | MAPTTP53LMNATHRBMEN1 | |
| SCHEMBL16254021 | 0.94 | POLB (0.60) | MAPTTP53LMNATHRBMEN1 | |
| SCHEMBL9930905 | 0.94 | MAPT (0.61) | MAPTTP53LMNATHRBMEN1 | |
| SCHEMBL12966481 | 0.94 | MAPT (0.59) | MAPTTP53LMNATHRBMEN1 | |
| SCHEMBL12966267 | 0.94 | MAPT (0.59) | MAPTTP53LMNATHRBMEN1 | |
| SCHEMBL12966323 | 0.94 | MAPT (0.59) | MAPTTP53LMNATHRBMEN1 | |
| SCHEMBL9970156 | 0.94 | LNPEP (0.60) | MAPTTP53LMNATHRBTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013123574-A1 | ORALLY BIOAVAILABLE DERIVATIVES OF D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-08-29 | — | — | WO | disclosed |
| US-20120157387-A1 | ORALLY BIOAVAILABLE D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157387-A1 | ORALLY BIOAVAILABLE D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | TPH1, TPH2, GLUL | MAPT 1759/4885TP53 1708/4885LMNA 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.